A new federal research grant is set to deepen understanding of how exposure to per- and polyfluoroalkyl substances (PFAS) affects children’s health, as MaineHealth secures $1.1 million in funding from the US National Institutes of Health (NIH). The development, first reported by Innovation News Network in its article “MaineHealth secures $1.1M NIH funding to advance PFAS exposure research in children”, reflects growing concern among public health experts about the long-term impacts of so-called “forever chemicals.”
PFAS, a broad class of synthetic chemicals used in products ranging from nonstick cookware to firefighting foam, are known for their environmental persistence and ability to accumulate in the human body. Increasingly, researchers are focusing on how early-life exposure may influence developmental and immune system outcomes, particularly in communities with known contamination. More background on these substances can be found via the U.S. Environmental Protection Agency’s PFAS overview.
The MaineHealth Institute for Research will lead the newly funded effort, which is expected to examine how PFAS exposure affects biological pathways in children. By leveraging clinical data and biospecimens, the research team aims to identify measurable changes linked to exposure, potentially offering earlier indicators of risk than traditional epidemiological approaches. Additional research context is available through the National Institute of Environmental Health Sciences PFAS resources.
The NIH funding underscores the urgency of addressing PFAS-related health questions at a time when contamination has been detected in water supplies, soil, and food systems across the United States. Maine, in particular, has emerged as a focal point due to documented contamination tied to agricultural practices, including the historical use of PFAS-laden sludge as fertilizer, as detailed by the Maine Department of Environmental Protection.
Researchers involved in the project plan to explore how PFAS may disrupt immune responses, metabolism, and other key physiological processes during childhood. Such insights could help explain observed associations between PFAS exposure and increased risk of conditions such as reduced vaccine effectiveness, developmental delays, and certain chronic diseases, topics also discussed by the Centers for Disease Control and Prevention.
Beyond advancing scientific knowledge, the findings are expected to inform public health strategies and regulatory decisions. Understanding which biological markers signal harm could support earlier intervention and guide policies aimed at limiting exposure, especially among vulnerable populations.
The award also reflects a broader shift in federal research priorities toward environmental health risks that disproportionately affect children. By focusing on early exposure and its long-term consequences, the MaineHealth-led study seeks to contribute to a growing body of evidence that may shape both clinical practice and environmental regulation in the years ahead, aligning with broader efforts by the National Institutes of Health.
As Innovation News Network highlighted, the grant represents a significant step in addressing unanswered questions about PFAS and underscores the role of targeted biomedical research in confronting complex environmental challenges.
